News ImmuneRegen NewsImmuneRegen BioSciences and Oak Ridge National Laboratory Announce Initial Results From Radilex(TM) TestingFirst Round of Final Mouse Studies Suggest Possible Applications for Treatment for Neutropenia and Anemia SCOTTSDALE, Ariz., June 1 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, Inc. a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), has announced the first round results from its Radilex(TM) studies on Acute Radiation Sickness (ARS) at the Oak Ridge National Laboratory (ORNL). Studies utilizing a mouse model of lethal whole body gamma irradiation suggest that Radilex™ might have possible applications for treatment of neutropenia and anemia following radiation exposure. In a preliminary experiment performed at Oak Ridge National Laboratory, Tennessee, animals exposed to lethal radiation (6 Gray to 8 Gray) but which survived following Radilex™ treatment apparently had higher levels of the infection-fighting white blood cells and higher levels of oxygen-carrying red blood cells than did animals that were not treated with Radilex™ and that died after radiation exposure. The project manager for the study, Dr. Dabney Johnson of Oak Ridge National Laboratory, stated that while the differences did not reach statistical significance, " ... more mice survived 8 Gy dose than should have survived, suggesting efficacy of drug treatment." Michael Wilhelm, the CEO of IR BioSciences Holdings, Inc. stated, "While these preliminary results are encouraging, we are in the early stages of development. Although we feel extremely positive, I need to express a cautionary optimism in that animal studies do not necessarily mean Radilex™ will work in people." Upcoming studies at ORNL will be designed to further these observations and provide more detailed insights into the possible therapeutic benefits of Radilex™. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|